DIADIA0.32%
SPYSPY0.27%
QQQQQQ0.29%
Trending
Top trending tickerBTCBTC6.99%
ETHETH6.47%
BCRXBCRX
LTCLTC5.21%
INDO0.76%
SLSSLS1.32%
LMTLMT0.30%
KRKNF1.76%
EWYEWY5.33%
IBRXIBRX7.20%
Top trending tickerBTCBTC6.99%
ETHETH6.47%
BCRXBCRX
LTCLTC5.21%
INDO0.76%
SLSSLS1.32%
LMTLMT0.30%
KRKNF1.76%
EWYEWY5.33%
IBRXIBRX7.20%
homeSymbolFEMY

FEMY
Femasys Inc

4,126
Mkt Cap
$32.08M
Volume
350.00
52W High
$1.76
52W Low
$0.3067
PE Ratio
-0.75
FEMY Fundamentals
Price
$0.5294
Prev Close
$0.538
Open
$0.545
50D MA
$0.6002
Beta
0.88
Avg. Volume
481,792.61
EPS (Annual)
-$0.845
P/B
5.59
Rev/Employee
$22,945.18
$28.48
Loading...
Loading...

Feed

News

Sentiment

Fundamentals

Info

News
all
press releases
Femasys (NASDAQ:FEMY) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Femasys from a "sell" rating to a "hold" rating in a research note on Friday...
MarketBeat·3mo ago
News Placeholder
More News
News Placeholder
PMCB Stock Jumps 25% After Company Sells Stake In Femasys
PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.
Stocktwits·3mo ago
News Placeholder
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing
Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.
Stocktwits·4mo ago
News Placeholder
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
Femasys (FEMY) delivered earnings and revenue surprises of +11.11% and -48.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
News Placeholder
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
News Placeholder
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
News Placeholder
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up
The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday.
Stocktwits·9mo ago
News Placeholder
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
chainwire·10mo ago
News Placeholder
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic
The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.
Stocktwits·11mo ago
<
...
1
>

Latest FEMY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.